Dipharma Francis S.r.l., a contract development and manufacturing organization (CDMO) and a global manufacturer of active pharmaceutical ingredients (APIs), reported that its production site in Caronno Pertusella, near Milan, Italy, has received the good manufacturing practice (GMP) certification – CBPF (Certificado de Boas Práticas de Fabricação) – from the regulatory authority of Brazil, ANVISA (Agência Nacional de Vigilância Sanitária).

The company received a previous authorization in November 2022, by the Dipharma Italian site located in Baranzate (Milan) and certifies Dipharma world-class quality system. The Caronno Pertusella facility has been regularly and successfully inspected by the U.S. FDA and the Italian Ministry of Health (AIFA) for more than 50 years.

“We are very proud to have reached another regulatory milestone: this second successful completion of the ANVISA certification recognizes another Dipharma site as being in compliance with the GMP requisites as foreseen by the Brazilian requirements,” said Jorge Nogueira, CEO Dipharma Francis S.r.l. “Our company is committed to providing innovative and competitive solutions to our customers and this achievement once again certifies we are an ideal partner for registering new applications at ANVISA.”